Verastem (VSTM) Competitors $7.43 -0.06 (-0.80%) Closing price 04:00 PM EasternExtended Trading$7.38 -0.04 (-0.61%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VSTM vs. MNKD, CLDX, DVAX, INVA, NVAX, OPK, GERN, MYGN, ZBIO, and RIGLShould you be buying Verastem stock or one of its competitors? The main competitors of Verastem include MannKind (MNKD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Myriad Genetics (MYGN), Zenas Biopharma (ZBIO), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry. Verastem vs. MannKind Celldex Therapeutics Dynavax Technologies Innoviva Novavax OPKO Health Geron Myriad Genetics Zenas Biopharma Rigel Pharmaceuticals Verastem (NASDAQ:VSTM) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Which has stronger valuation & earnings, VSTM or MNKD? MannKind has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerastem$10M38.59-$87.37M-$3.50-2.14MannKind$285.50M5.25-$11.94M$0.1049.35 Do analysts recommend VSTM or MNKD? Verastem currently has a consensus target price of $13.89, indicating a potential upside of 85.31%. MannKind has a consensus target price of $9.56, indicating a potential upside of 93.77%. Given MannKind's stronger consensus rating and higher possible upside, analysts plainly believe MannKind is more favorable than Verastem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verastem 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00MannKind 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the media prefer VSTM or MNKD? In the previous week, Verastem had 3 more articles in the media than MannKind. MarketBeat recorded 11 mentions for Verastem and 8 mentions for MannKind. MannKind's average media sentiment score of 1.70 beat Verastem's score of 0.82 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility and risk, VSTM or MNKD? Verastem has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Do insiders and institutionals hold more shares of VSTM or MNKD? 88.4% of Verastem shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 2.1% of Verastem shares are held by company insiders. Comparatively, 3.0% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor VSTM or MNKD? Verastem received 29 more outperform votes than MannKind when rated by MarketBeat users. Likewise, 65.33% of users gave Verastem an outperform vote while only 60.41% of users gave MannKind an outperform vote. CompanyUnderperformOutperformVerastemOutperform Votes61865.33% Underperform Votes32834.67% MannKindOutperform Votes58960.41% Underperform Votes38639.59% Is VSTM or MNKD more profitable? MannKind has a net margin of 8.07% compared to Verastem's net margin of 0.00%. MannKind's return on equity of -17.74% beat Verastem's return on equity.Company Net Margins Return on Equity Return on Assets VerastemN/A -332.73% -73.97% MannKind 8.07%-17.74%8.68% SummaryMannKind beats Verastem on 13 of the 19 factors compared between the two stocks. Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VSTM vs. The Competition Export to ExcelMetricVerastemPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$385.92M$6.74B$5.50B$7.96BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-2.357.3822.6318.55Price / Sales38.59241.88397.30103.38Price / CashN/A65.8538.1834.62Price / Book3.306.476.704.25Net Income-$87.37M$143.68M$3.23B$248.27M7 Day Performance-0.07%1.85%1.36%1.28%1 Month Performance28.78%6.73%3.85%3.75%1 Year Performance-24.90%-2.72%15.87%5.31% Verastem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VSTMVerastem3.2107 of 5 stars$7.43-0.8%$13.89+86.9%-24.9%$385.66M$10M-2.3350Upcoming EarningsAnalyst RevisionMNKDMannKind3.1264 of 5 stars$4.73-0.2%$9.56+102.2%+22.6%$1.44B$285.50M67.57400Upcoming EarningsPositive NewsCLDXCelldex Therapeutics1.9863 of 5 stars$21.36+9.1%$55.30+158.9%-44.3%$1.42B$7.02M-8.31150Analyst ForecastPositive NewsDVAXDynavax Technologies4.3659 of 5 stars$11.27+4.2%$20.50+81.9%+3.3%$1.38B$277.25M62.61350Upcoming EarningsINVAInnoviva4.2219 of 5 stars$18.38+0.8%$55.00+199.2%+23.7%$1.15B$358.71M26.64100Upcoming EarningsAnalyst UpgradeNews CoveragePositive NewsNVAXNovavax3.6182 of 5 stars$6.71+0.6%$18.00+168.3%+54.0%$1.08B$682.16M-2.971,990OPKOPKO Health4.4735 of 5 stars$1.41flat$2.75+95.0%+13.1%$946.89M$713.14M-7.424,200Earnings ReportAnalyst ForecastNews CoverageGap DownGERNGeron3.9984 of 5 stars$1.40-1.4%$5.75+310.7%-64.1%$891.68M$76.99M-4.3870Upcoming EarningsMYGNMyriad Genetics4.1138 of 5 stars$7.50+1.1%$20.61+174.8%-62.1%$691.28M$837.60M-5.772,600Upcoming EarningsHigh Trading VolumeZBIOZenas BiopharmaN/A$9.95-0.7%$40.00+302.0%N/A$415.90M$5M-2.80N/ARIGLRigel Pharmaceuticals2.7513 of 5 stars$19.41+0.7%$36.80+89.6%+86.3%$346.80M$179.28M138.65160Upcoming Earnings Related Companies and Tools Related Companies MannKind Alternatives Celldex Therapeutics Alternatives Dynavax Technologies Alternatives Innoviva Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Myriad Genetics Alternatives Zenas Biopharma Alternatives Rigel Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VSTM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VSTM Stock Free VSTM Stock Alerts